Healthcare's Valuation Disconnect Signals Opportunity for Asia's Wealth Allocators
The healthcare sector is currently trading at a significant discount to the broader market, presenting a compelling opportunity for wealth allocators in Asia. This undervaluation, which has persisted for over a decade, is a result of various factors, including political uncertainty in the United States, rising interest rates, and the surge in capital towards AI and technology stocks. However, beneath this headline weakness lies a sector with robust fundamentals and an unmatched innovation pipeline, making it an attractive entry point for investors.
One of the key challenges in the healthcare sector has been its underperformance, which has been exacerbated by political uncertainty in the US and the significant capital flowing into AI and tech. This has led to a sentiment that the sector is 'out of favor'. However, a closer look reveals a sector with strong fundamentals across multiple sub-sectors, particularly in the pharmaceutical and large-cap biotech space.
The resolution of the most-favored-nation pricing dispute with the US government late last year has effectively removed a significant political overhang on the sector, stabilizing pharma and large-cap biotech shares. Small and mid-cap biotech names have also performed well, driven by strong clinical results and a surge in acquisition activity from large pharma companies seeking to replenish their depleted pipelines.
Healthcare providers, especially US health insurance companies, have faced challenges due to rising medical costs among the elderly population. However, the first-quarter 2026 results marked a turning point, as premiums were high enough to absorb the underlying medical costs, indicating a positive trend in the sector.
Medtech, on the other hand, remains under pressure, trading down 16% year-to-date in dollar terms. This is largely attributed to uncertainty around the US government's decision not to extend Affordable Care Act subsidies for 2026, raising concerns about the sustainability of procedure growth.
The valuation case for healthcare is compelling, with the MSCI World Healthcare Index trading at approximately 17 times next-12-month earnings, compared to 21 times for the S&P 500. On a relative basis, healthcare's price-to-earnings (P/E) ratio is well below the 10-year average, presenting an opportunity for investors to build healthcare exposure at attractive levels.
Within medtech, the valuation dislocation is even more pronounced, with the sub-sector trading at around 18 times earnings, despite delivering strong organic revenue and earnings growth. This presents a promising opportunity, but it requires catalysts to drive the multiples higher.
Innovation is a key driver of growth in the healthcare sector. New products and treatment modalities are creating entirely new revenue pools. For instance, lipoprotein(a) (Lp(a)) represents a multi-billion-dollar market opportunity, with several companies in late-stage trials. Robotic surgery is also advancing, with Intuitive Surgical's Da Vinci 5 system incorporating AI-driven features for simulated surgical training and tissue pressure sensing.
AI is emerging as a cost and efficiency lever in the healthcare sector, rather than a disruptive threat. In pharma and biotech, AI is being used to accelerate drug development, improve patient selection for clinical trials, and predict toxicity profiles, potentially saving billions in drug development costs. For health insurance companies, AI enables automation of invoice processing and contract management.
M&A is a structural imperative for big pharma, with hundreds of billions of dollars in revenue at risk due to patent expirations. The 20 largest biopharma companies collectively hold over $1 trillion in combined cash and debt capacity, and major transactions in 2025 and early 2026 underscore the ongoing M&A cycle.
For wealth managers and family office professionals, healthcare remains structurally underweight in most portfolios, despite its defensive qualities and innovation-driven growth. The sector's domain expertise and long-term growth potential make it an increasingly logical complement to concentrated technology positions.
Bellevue Asset Management, a specialist healthcare equity manager, positions itself as a partner for investors seeking differentiated healthcare exposure. With a focus on publicly listed healthcare equities and a team of investment professionals with diverse backgrounds, Bellevue is making the case that the current dislocation represents a window of opportunity that disciplined allocators should not ignore.
